MGN 1404

Drug Profile

MGN 1404

Alternative Names: MGN-1404

Latest Information Update: 29 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mologen
  • Developer Charite of Berlin; Max-Delbruck Centre for Molecular Medicine; Mologen
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Tumour necrosis factor alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 09 Jun 2016 Discontinued - Phase-I for Malignant melanoma in Germany (Intratumoural)
  • 18 Oct 2013 Phase-I clinical trials in Malignant melanoma in Germany (Intratumoural)
  • 15 Apr 2013 The Paul-Ehrlich Institute grants approval for a phase I trial in Malignant melanoma in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top